Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Lear
LEA
$8.56B
| $61.9M | 0.08% |
461,477
+431,368
| +1,433% | +$57.8M |
|
|
EXE
302
Expand Energy Corp
EXE
$22.2B
| $61.6M | 0.08% |
675,722
+19,795
| +3% | +$1.88M |
|
303
Ameren
AEE
$29.4B
| $61.3M | 0.08% |
542,649
-201,708
| -27% | -$22.3M |
|
304
Arthur J. Gallagher & Co
AJG
$67.6B
| $61.3M | 0.08% |
267,170
+28,183
| +12% | +$5.98M |
|
305
Texas Roadhouse
TXRH
$13.4B
| $61M | 0.08% |
+315,756
| New | +$53.8M |
|
306
Cytokinetics
CYTK
$10.7B
| $60.6M | 0.08% |
711,676
-280,869
| -28% | -$20.2M |
|
307
BioMarin Pharmaceuticals
BMRN
$12.9B
| $60.3M | 0.08% |
1,054,613
-308,139
| -23% | -$16.9M |
|
308
American Airlines Group
AAL
$9.15B
| $60.2M | 0.08% |
+3,329,378
| New | +$44.6M |
|
309
Amer Sports
AS
$19B
| $60M | 0.07% |
1,771,646
-2,229,684
| -56% | -$78.1M |
|
310
MGM Resorts International
MGM
$11B
| $59.5M | 0.07% |
1,244,866
+887,225
| +248% | +$36.9M |
|
311
Broadcom
AVGO
$1.75T
| $59.4M | 0.07% |
157,244
-339,410
| -68% | -$136M |
|
312
Bio-Techne
TECH
$11.3B
| $59.1M | 0.07% |
+836,870
| New | +$45.2M |
|
313
Onto Innovation
ONTO
$17.9B
| $58.6M | 0.07% |
154,951
-50,705
| -25% | -$14.3M |
|
314
Quest Diagnostics
DGX
$27B
| $58.4M | 0.07% |
275,371
+272,473
| +9,402% | +$53.5M |
|
315
Everest Group
EG
$14.2B
| $57.9M | 0.07% |
162,213
-127,699
| -44% | -$43.7M |
|
316
Biogen
BIIB
$32B
| $57.3M | 0.07% |
265,090
-384,956
| -59% | -$73.6M |
|
317
Mirum Pharmaceuticals
MIRM
$5.87B
| $57.3M | 0.07% |
489,170
-49,861
| -9% | -$5.01M |
|
318
SS&C Technologies
SSNC
$19.5B
| $57.2M | 0.07% |
+922,003
| New | +$62.6M |
|
319
Coupang
CPNG
$29.6B
| $57.2M | 0.07% |
+3,290,427
| New | +$59.4M |
|
320
PUT
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$46.4B
| $56.8M | 0.07% |
108,700
+46,200
| +74% | +$23.1M |
|
321
Nasdaq
NDAQ
$54.9B
| $56.8M | 0.07% |
720,374
+300,281
| +71% | +$26.3M |
|
322
PUT
CrowdStrike
CRWD
$195B
| $56.6M | 0.07% |
296,800
-179,200
| -38% | -$25.5M |
|
323
PUT
Walt Disney
DIS
$186B
| $56.6M | 0.07% |
588,000
-1,708,100
| -74% | -$174M |
|
324
Evergy
EVRG
$18.7B
| $56.4M | 0.07% |
653,048
+452,352
| +225% | +$37.5M |
|
325
Celanese
CE
$5.14B
| $56.2M | 0.07% |
1,222,460
+484,050
| +66% | +$28M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.